Pipeline activity
A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia
Pressure score
53
Momentum score
5
Why This Matters
Lilly is a direct competitive threat because it has a development-stage program in Cardiology · LDL-C lowering (Pipeline activity) and could narrow Novartis's development lead.
Competitive Assessment
- Threat type
- direct competitor
- Development stage
- Stage unknown
- Stage gap
- Stage comparison unavailable — competitor development phase not fully evidenced.
- Market share risk
- Share risk is emerging — primarily strategic positioning rather than immediate revenue displacement.
Strategic Action
Align with signal posture: monitor. Monitor direct competitor activity and refresh competitive intelligence after material readouts.
Overlap Analysis
Source Analysis
A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia
Lilly's Pipeline activity directly references the same indication focus (Cardiology · LDL-C lowering) as this signal.
Source: Lilly
View source documentRelated Signal
Novartis initiates trial for inclisiran in acute coronary syndromes
Open signalCompetitor Position
Competitor race
Pressure ranking for this signal's competitive set
Position: #1 of 2
Lilly
1 competitive finding
Top program: Pipeline activity
- Pressure
- 53
- Momentum
- 5
- Threat
- direct competitor
- Stage
- Stage unknown
53LillyMediumPipeline activity·Stage unknown
Merck
1 competitive finding
Top program: Pipeline activity
- Pressure
- 52
- Momentum
- 5
- Threat
- direct competitor
- Stage
- Stage unknown
52MerckMediumPipeline activity·Stage unknown